
    
      This trial consists of 2 studies. Seven consecutive patients will be enrolled to a phase 1a
      study to verify the procedural feasibility and safety, followed by a phase 1b study to
      randomly assign 24 patients in a 1:1 ratio to the CDC infusion group and the control arm.
    
  